NCT02729298View on ClinicalTrials.gov

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

177

Participants

Timeline

Start Date

December 14, 2016

Primary Completion Date

June 29, 2022

Study Completion Date

June 29, 2022

Conditions
Advanced Solid TumorsEGFR Positive Non-small Cell Lung CancerColorectal CarcinomaRecurrent Ovarian CarcinomaBRAF-Mutated Melanoma
Interventions
DRUG

TP-0903

Novel oral inhibitor that targets AXL kinase and reverses the mesenchymal phenotype associated with advanced cancers

Trial Locations (16)

22031

US Oncology - Virginia Cancer Specialists (VCS), Fairfax

32224

Mayo Clinic Florida, Jacksonville

33176

Miami Cancer Institute, Miami

53226

Medical College of Wisconsin, Milwaukee

55905

Mayo Clinic Rochester, Rochester

66205

University of Kansas Cancer Center, Fairway

75390

University of Texas Southwestern Medical Center, Dallas

75702

US Oncology - Texas Oncology - Tyler, Tyler

76104

US Oncology - Texas Oncology - Fort Worth, Fort Worth

78229

University of Texas Science Center at San Antonio (UTHSCSA), San Antonio

78705

US Oncology - Texas Oncology Austin, Austin

80045

University of Colorado Denver, Denver

80218

US Oncology - Rocky Mountain Cancer Centers, LLP (RMCC), Denver

85054

Mayo Clinic Arizona, Phoenix

85258

HonorHealth Research Institute, Scottsdale

97401

US Oncology - Willamette Valley Cancer Institute and Research Center, Eugene

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT02729298 - First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter